Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01209325 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
A Phase 2 study, sponsored by AIDS Malignancy Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 149
- Enrollment target
NCT01209325 is a Phase 2 study that has completed, run by AIDS Malignancy Consortium. The registered enrollment target is 149 participants.
The verdict
NCT01209325, a Phase 2 study, has completed, sponsored by AIDS Malignancy Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 149 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to prevent viral infection. PURPOSE: This phase II trial is studying how well vaccine therapy works in preventing human papillomavirus (HPV) infection in young HIV-positive male patients who have sex with males.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2011-06-28 |
| Est. Completion | 2017-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01209325
The ClinicalTrials.gov registry entry for NCT01209325 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01209325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01209325 about?
NCT01209325 is a clinical study titled "Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males". RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to prevent viral infection. PURPOSE: This phase II trial is studying how well vaccine therapy works in preventing human papillomavirus (HPV) infection in young HIV-positive male patients who hav...
What is the current status of trial NCT01209325?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 149 participants. The study started on 2011-06-28. Estimated completion is 2017-12-12.
What interventions are being tested in trial NCT01209325?
The interventions under investigation include: laboratory biomarker analysis (OTHER), quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01209325?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.